跳至主要内容
临床试验/NCT01831193
NCT01831193已完成3 期

Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease

Instituto Nacional de Cardiologia Ignacio Chavez1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
120
试验地点
1
主要终点
Change in proteinuria

研究概览

简要总结

The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.

详细描述

Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa L.

Different studies have demonstrated that curcumin has potent biological activity and therefore is an effective therapeutic agent for the treatment of various ailments.

This compound acts as a bifunctional antioxidant:

ه is capable of reacting directly with highly reactive oxygen species. ه acts indirectly by its ability to induce the expression of various cytoprotective proteins through Keap1/Nrf2/ARE pathway.

Although RAAS blockade is the cornerstone to prevent the progression of proteinuric nephropathy, a significant number of patients remained with proteinuria and progress to end-stage renal disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a daily recollection.
  • Individuals taking Angiotensin II Receptor Blocker or ACE inhibitors in monotherapy with maximum dose or in combination.

排除标准

  • Hepatic damage.
  • Malignancy.
  • Pregnancy.
  • Peritoneal or hemodialysis.
  • Organ transplantation.
  • Heart failure classification III or IV (New York Heart Association).
  • History of chemotherapy within 2 years prior to screening.

研究组 & 干预措施

Diabetic

Active Comparator

干预措施: Curcumin (Drug)

Non-diabetic

Active Comparator

干预措施: Curcumin (Drug)

结局指标

主要结局

Change in proteinuria

时间窗: 8 weeks

次要结局

未报告次要终点

研究者

发起方
Instituto Nacional de Cardiologia Ignacio Chavez
申办方类型
Other
责任方
Principal Investigator
主要研究者

Magdalena Madero

MD

Instituto Nacional de Cardiologia Ignacio Chavez

研究点 (1)

Loading locations...

相似试验